Skip to main content

Table 1 Correlation between clinicopathological features and RCB-TILs in 177 breast cancers

From: Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden

Parameters

RCB-TILs in all breast cancers (n = 177)

p value

Positive (n = 112)

Negative (n = 65)

 

Age at operation

 ≤ 56

52 (46.4%)

35 (53.9%)

 

 > 56

60 (53.6%)

30 (46.1%)

0.341

Menopause

 Pre-menopausal

44 (39.3%)

28 (43.1%)

 

 Post-menopausal

68 (60.7%)

37 (56.9%)

0.621

Tumor size

 ≤ 2 cm

19 (17.0%)

5 (7.7%)

 

 > 2 cm

93 (83.0%)

60 (92.3%)

0.082

Lymph node status

   

 Negative

27 (24.1%)

14 (21.5%)

 

 Positive

85 (75.9%)

51 (78.5%)

0.696

Nuclear grade

 1, 2

81 (72.3%)

56 (86.2%)

 

 3

31 (27.7%)

9 (13.8%)

0.034

Ki67

 ≤ 14%

36 (32.1%)

38 (58.5%)

 

 > 14%

76 (67.9%)

27 (41.5%)

0.001

Intrinsic subtype

 TNBC

49 (43.8%)

12 (16.0%)

 

 non-TNBC

63 (56.2%)

53 (84.0%)

0.001

Intrinsic subtype

 HER2BC

26 (23.2%)

10 (15.4%)

 

 non- HER2BC

86 (76.8%)

55 (84.6%)

0.212

Intrinsic subtype

 HRBC

37 (33.0%)

43 (66.2%)

 

 non-HRBC

75 (67.0%)

22 (33.8%)

<0.001

Pathological response

 pCR

58 (51.8%)

9 (13.8%)

 

 non-pCR

54 (48.2%)

56 (86.2%)

<0.001

  1. RCB residual cancer burden, TILs tumor-infiltrating lymphocytes, TNBC triple-negative breast cancer, HER2BC human epidermal growth factor receptor 2-enriched breast cancer, HRBC hormone receptor-positive breast cancer, pCR pathological complete response